Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alzamend NeuroALZN +0.75%21 EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus rates ALZN with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 939 Biotechnology companies, Alzamend Neuro ranks worse than 106496.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Alzamend Neuro's EBITDA for the
three
months ended in Apr. 2026 was $-2.84 Mil. Alzamend Neuro's Revenue for the
three
months ended in Apr. 2026 was $0.00 Mil. Therefore, Alzamend Neuro's EBITDA margin for the quarter that ended in Apr. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Alzamend Neuro EBITDA Margin % Related Terms
Alzamend Neuro EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Alzamend Neuro's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALZN vs SILO, BGMS, ENVB: EBITDA Margin % Comparison
For the Biotechnology subindustry, Alzamend Neuro's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro (ALZN) has a EBITDA Margin % of 0.00% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alzamend Neuro and its competitors. According to the industry distribution chart, Alzamend Neuro ranks #999999 out of 939 companies in the Biotechnology industry.
Is Alzamend Neuro's EBITDA Margin % too high?
Alzamend Neuro's current EBITDA Margin % is 0.00%. Based on the distribution chart, Alzamend Neuro ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alzamend Neuro has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzamend Neuro's EBITDA Margin % compare to SILO and BGMS?
According to the Biotechnology industry distribution chart, Alzamend Neuro ranks #999999 out of 939 companies for EBITDA Margin %. This places Alzamend Neuro in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alzamend Neuro and its competitors. Alzamend Neuro's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzamend Neuro stock overvalued right now?
Alzamend Neuro (ALZN) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Alzamend Neuro's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alzamend Neuro (ALZN), the current EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
21GF Score
Get the complete analysis for ALZN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALZN has been successfully added to your 
